Fasting Comparative Bioavailability Study of 2 Meloxicam 15 mg Tablets in Healthy Volunteers Under Fasting Condition

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

January 29, 2014

Primary Completion Date

February 26, 2014

Study Completion Date

February 26, 2014

Conditions
Pharmacokinetics
Interventions
DRUG

"Reumoxicam® 15 mg tablets (PJSC Farmak, Ukraine)"

One tablet was administered orally and swallowed at once, without chewing, by study volunteers, followed by 200 ml of water, under fasting condition (after preliminary nocturnal fasting for 12 hours) in the morning at 8:00 hours on Day I Period I and Period II of the study.

DRUG

"Movalis 15 mg tablets (Boehringer Ingelheim Ellas A.E., Greece)"

One tablet was administered orally and swallowed at once, without chewing, by study volunteers, followed by 200 ml of water, under fasting condition (after preliminary nocturnal fasting for 12 hours) in the morning at 8:00 hours on Day I Period I and Period II of the study.

All Listed Sponsors
lead

"Joint Stock Company Farmak"

INDUSTRY

NCT05125588 - Fasting Comparative Bioavailability Study of 2 Meloxicam 15 mg Tablets in Healthy Volunteers Under Fasting Condition | Biotech Hunter | Biotech Hunter